Information processing system, information processing method and program

Abstract

Provided is an information processing system comprising a first terminal, a second terminal, and a management system, wherein: the first terminal outputs a first hash value from data including at least target content and transmits first certification data including any of the first hash value or information based on the first hash value; the management system records, on blockchain, the first certification data received from the first terminal, reads the first certification data recorded on the blockchain and transmits the certification data to the second terminal; and the second terminal acquires the first hash value included in the first certification data received from the management system, acquires the target content and generates a second hash value from the target content, and determines whether the first hash value is matched with the second hash value.

Description

[Technical Field]

[0001] The present invention relates to an information processing system, an information processing method, and a program. [Background technology]

[0002] In previous cancer treatments, treatments and drugs were selected according to the type of cancer, such as lung cancer, colon cancer, or breast cancer. However, in the 2000s, progress was made in understanding the molecules (proteins) that cause cancer and the genetic mutations that underlie them, making it possible to use "molecularly targeted drugs" that act on these molecules and genes for treatment. Further developments in molecularly targeted drugs have also led to the development of treatments that target individual patient molecules and genetic mutations. Here, providing treatment tailored to each individual based not only on the type of cancer but also on the characteristics of the cancer, such as genetic mutations, is called "personalized treatment." Traditionally, "personalized treatment" based on cancer genetic information has mainly been carried out based on "cancer gene testing," which examines a small number of genes, and "cancer gene panel testing," which examines a large number of genes simultaneously.

[0003] In recent years, there has been progress in cancer immunotherapy (hereafter referred to as cancer vaccine therapy), which "uses the immune system, which humans naturally possess, to attack and eliminate cancer cells." One type of cancer vaccine therapy is known as a "peptide vaccine." Peptide vaccines contain antigens, which are markers of cancer. When peptides containing these antigens are directly injected into the body, the body's natural immune system detects an abnormality and targets the antigens, which are markers of cancer, to attack and kill the cancer cells.

[0004] In recent years, the genetic mutations of individual cancers can be comprehensively and easily identified. The importance of newly generated "peptides" resulting from these genetic mutations has been highlighted in cancer immunotherapy. These peptides are mutant peptides known as "neoantigens." When these peptides are transported to the surface of cancer cells via human leukocyte antigens (HLA), which are not present on the surface of normal cells, they are recognized as enemies by cytotoxic T lymphocytes (CTLs), enabling them to kill the cancer cells. Clinical trials using "neoantigens" to assess the effectiveness of personalized cancer vaccine therapy as a cancer treatment or recurrence prevention method are currently underway in Europe and the United States. Patent Document 1 also discloses a method for identifying polypeptide fragments that are immunogenic in specific human subjects and a method for preparing personalized pharmaceutical compositions containing these polypeptide fragments. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Special Publication No. 2020-510698 Summary of the Invention [Problem to be solved by the invention]

[0006] Because the types and numbers of mutant peptides known as "neoantigens" vary from patient to patient, it is necessary to produce a peptide vaccine from the genetic mutations in the patient's cancer tissue for each patient.In the case of personalized medicine (for example, personalized cancer vaccine therapy), there are three processes: a genetic analysis institution (for example, a sequence vendor) analyzes the genetic sequence of the patient's sample, a recipe creation institution creates a recipe for a drug (for example, a cancer vaccine) for the patient based on the genetic analysis results, and a drug manufacturing institution (for example, a pharmaceutical company) manufactures the drug (for example, a cancer vaccine) from this recipe.

[0007] In this way, the authenticity of the genetic sequence data (also called genomic information) of patient samples or vaccine data is required during the distribution process for creating personalized medicines (for example, cancer vaccines).

[0008] In addition, authenticity is required for specifications for medicines (such as personalized vaccines) that are exclusive to the target patient, and contracts for medicines (such as personalized vaccines) that are exclusive to the target patient.

[0009] In addition, there is a need for a system that guarantees the authenticity of the manufacturing report for a drug specifically for a target patient (e.g., an individualized vaccine), the product testing report for a drug specifically for a target patient (e.g., an individualized vaccine), the delivery note for a drug specifically for a target patient (e.g., an individualized vaccine), or the receipt for a drug specifically for a target patient (e.g., an individualized vaccine).

[0010] Thus, there is a need for a system that ensures the authenticity of target content (e.g., genome data, recipe data, etc.) in the distribution process for the production of medicines dedicated to target patients (e.g., personalized vaccines).The target content here includes the genome data of the target patient, recipe data for medicines dedicated to target patients (e.g., personalized vaccines), specifications for medicines dedicated to target patients (e.g., personalized vaccines), contracts for medicines dedicated to target patients (e.g., personalized vaccines), manufacturing reports for medicines dedicated to target patients (e.g., personalized vaccines), product testing reports for medicines dedicated to target patients (e.g., personalized vaccines), delivery documents for medicines dedicated to target patients (e.g., personalized vaccines), or receipts for medicines dedicated to target patients (e.g., personalized vaccines).

[0011] In addition to cancer vaccines, there is a similar possibility of treating autoimmune diseases, and similar problems exist with personalized medicines for autoimmune diseases.

[0012] This embodiment has been made in consideration of the above-mentioned problems, and one of its objectives is to provide an information processing system, information processing method, and program that can ensure the authenticity of target content during the distribution process in the creation of personalized medicine. [Means for solving the problem]

[0013] An information processing system according to a first aspect of the present invention is an information processing system comprising a first terminal, a second terminal, and a management system, wherein the first terminal outputs a first hash value from data including at least a target content, and transmits first certification data including the first hash value or information based on the first hash value, the management system records the first certification data received from the first terminal in a blockchain, the management system transmits the first certification data recorded in the blockchain to the second terminal, the second terminal obtains the first hash value from the first certification data received from the management system, obtains the target content, generates a second hash value from the target content, and determines whether the first hash value and the second hash value match.

[0014] An information processing system according to a second aspect of the present invention is an information processing system according to the first aspect, wherein the first terminal is used by a genetic analysis institution that generates genomic information of a target patient from a sample of the target patient, the second terminal is used by a recipe creation institution that creates a vaccine recipe, and the target content is genomic information of the target patient.

[0015] An information processing system according to a third aspect of the present invention is an information processing system according to the second aspect, wherein the genomic information of the subject patient includes genetic data of cancer cells of the subject patient and genetic data of normal cells of the subject patient.

[0016] An information processing system according to a fourth aspect of the present invention is an information processing system according to the first aspect, wherein the first terminal is used by a recipe creation institution that creates vaccine recipes, the second terminal is used by a drug manufacturing institution that manufactures personalized medicines from vaccine recipes, and the target content is a vaccine recipe for a target patient.

[0017] An information processing system according to a fifth aspect of the present invention is an information processing system according to any one of the first to fourth aspects, wherein the information based on the first hash value is the first hash value encrypted with a first private key, and when transmitting the first proof data, the first terminal transmits the first hash value encrypted with the first private key, and when obtaining the first hash value included in the first proof data, the second terminal obtains the first hash value by decrypting the first proof data with a first public key corresponding to the first private key.

[0018] An information processing system according to a sixth aspect of the present invention is an information processing system according to any one of the first to fifth aspects, wherein the first certification data received from the first terminal and recorded in the blockchain includes drug identification information that identifies personalized medicine for the target patient, and when the first hash value and the second hash value match, the second terminal transmits second certification data including the drug identification information and the first hash value or the second hash value, and the management system records the second certification data received from the second terminal in the blockchain.

[0019] An information processing system according to a seventh aspect of the present invention is an information processing system according to the sixth aspect, further comprising an authentication system, which searches a block of a blockchain using the target drug identification information as a key, and if the hash values ​​contained in the two blocks obtained as a result of the search match, determines that the transfer of the target content has been carried out normally.

[0020] An information processing system according to an eighth aspect of the present invention is an information processing system according to the second or third aspect, further comprising a third terminal used by a drug manufacturing institution that manufactures personalized medicines from vaccine recipes, wherein the second terminal outputs a hash value from data including at least a drug recipe for a target patient and transmits third certification data including either the hash value or information based on the hash value, the management system records the third certification data received from the second terminal in a blockchain, the management system transmits the third certification data recorded in the blockchain to the third terminal, the third terminal obtains a fourth hash value included in the third certification data received from the management system, obtains the recipe and generates a fourth hash value from the recipe, and determines whether the third hash value and the fourth hash value match.

[0021] An information processing system according to a ninth aspect of the present invention is an information processing system according to the eighth aspect, wherein when transmitting the third proof data, the second terminal transmits the third hash value encrypted with a second private key, and when obtaining the third hash value included in the third proof data, the third terminal obtains the second hash value by decrypting the third proof data with a second public key corresponding to the second private key.

[0022] An information processing system according to a tenth aspect of the present invention is an information processing system according to the eighth or ninth aspect, wherein the third certification data received from the second terminal and recorded in the blockchain includes drug identification information that identifies personalized medicine for the target patient, and if the third hash value and the fourth hash value match, the third terminal transmits fourth certification data including the drug identification information and the third hash value or the fourth hash value, and the management system records the fourth certification data received from the third terminal in the blockchain.

[0023] An information processing system according to an eleventh aspect of the present invention is an information processing system according to any one of the first to tenth aspects, comprising a fourth terminal used by a medical institution and a fifth device used by a logistics company, wherein the fourth terminal transmits fifth certification data to certify that the medical institution has handed over the target patient's sample to the logistics company, the management system records the fifth certification data received from the fourth terminal in the blockchain, the fifth terminal transmits sixth certification data to certify that the logistics company has received the target patient's sample from the medical institution, and the management system records the sixth certification data received from the fifth terminal in the blockchain.

[0024] An information processing system according to a 12th aspect of the present invention is an information processing system according to the 11th aspect, wherein the fifth certification data includes a hash value of text data for personalized medicine encrypted with a third private key for a medical institution, and the sixth certification data includes a hash value of text data for personalized medicine encrypted with a fourth private key for a logistics company.

[0025] An information processing method according to a thirteenth aspect of the present invention includes the steps of: a first terminal outputting a first hash value from data including at least a target content, and transmitting first proof data including either the first hash value or information based on the first hash value; a management system recording the first proof data received from the first terminal in a blockchain; the management system transmitting the first proof data recorded in the blockchain to the second terminal; and the second terminal obtaining the first hash value from the first proof data received from the management system, obtaining the target content, generating a second hash value from the target content, and determining whether the first hash value and the second hash value match.

[0026] A program according to a fourteenth aspect of the present invention is a program for causing a computer to execute the following steps: obtaining a first hash value from first proof data recorded in a blockchain, the first proof data including either a first hash value generated from data including at least the target content or information based on the first hash value; generating a second hash value from the target content; and determining whether the first hash value and the second hash value match. [Effects of the Invention]

[0027] According to one aspect of the present invention, if the first hash value recorded in the blockchain matches the second hash value generated from the target content, it is guaranteed that the two are the same target content, thereby ensuring the authenticity of the target content. [Brief explanation of the drawings]

[0028] [Figure 1] The configuration of the information processing system according to this embodiment will be described. [Figure 2] FIG. 2 is a schematic configuration diagram of a terminal according to the present embodiment. [Figure 3] 1 is a schematic configuration diagram of a management system according to an embodiment of the present invention; [Figure 4] 1 is a schematic configuration diagram of an authentication system according to an embodiment. [Figure 5] FIG. 1 is a schematic diagram showing an example of an outline of the process of creating a personalized medicine. [Figure 6] FIG. 10 is a schematic diagram showing an example of a flow of transfer of a target content file. DETAILED DESCRIPTION OF THE INVENTION

[0029] Hereinafter, each embodiment will be described with reference to the drawings. However, unnecessary detailed description may be omitted. For example, detailed description of well-known matters or redundant description of substantially the same configuration may be omitted. This is to avoid unnecessary redundancy in the following description and to facilitate understanding by those skilled in the art.

[0030] Furthermore, in the distribution process of creating personalized medicines (for example, cancer vaccines), there is a need for a system that ensures that the genetic analysis organization that generated the data is the party that created the genetic sequence data (also known as genome data) of patient specimens.Similarly, in the distribution process of creating personalized medicines (for example, cancer vaccines), there is a need for a system that ensures that the recipe creation organization that created the vaccine recipe is the party that created the vaccine recipe.

[0031] Similarly, there is a need for a system to ensure that the institution that prepares the specifications for medicines (such as personalized vaccines) specifically for target patients and the contracts for medicines (such as personalized vaccines) specifically for target patients is the party that prepared them.

[0032] Similarly, there is a need for a system that guarantees that the institution that created the manufacturing report for a drug specifically for a target patient (e.g., an individualized vaccine), the product testing report for a drug specifically for a target patient (e.g., an individualized vaccine), the delivery note for a drug specifically for a target patient (e.g., an individualized vaccine), or the receipt for a drug specifically for a target patient (e.g., an individualized vaccine) is the party that created it.

[0033] In addition to or instead of the above-mentioned issues, there is a need for a system that ensures the authenticity of the creators of the target content in the distribution process of personalized medicine creation.

[0034] The configuration of an information processing system according to this embodiment is explained with reference to Fig. 1. As shown in Fig. 1, the information processing system 10 includes a terminal 1 used by a genetic analysis institution, a terminal 2 used by a recipe creation institution, a terminal 3 used by a drug manufacturing institution, a terminal 4 used by a medical institution, and a terminal 5 used by a logistics company.

[0035] Here, the genetic analysis institution generates genomic information (also called genetic data) of a target patient from a specimen of the target patient. The specimen of the target patient may include, for example, cancer tissue and normal tissue of the same target patient. In this case, the generated genomic information of the target patient is genetic data (e.g., DNA data) of the target patient's cancer cells and genetic data (e.g., DNA data) of the target patient's normal cells. The recipe creation institution creates a vaccine recipe.

[0036] The information processing system 10 further includes a management system 6, an authentication system 7, a distributed network 8 for blockchain, and a storage 9. Each of the terminals 1 to 5, the authentication system 7, and the storage 9 is communicatively connected to the management system 6 via a communication network CN. Here, the terminals 1 to 5 are, for example, computers such as smartphones, tablet terminals, laptops, or personal computers. Each of the terminals 1 to 5 has at least one processor and at least one memory, and stores a unique private key. The authentication system 7 stores public keys corresponding to the private keys held by each of the terminals 1 to 5. The storage 9 stores data of the target content (e.g., genetic data, vaccine recipe data, etc.).

[0037] The distributed network 8 includes multiple computers (not shown), and these terminals are connected to each other so that they can communicate with each other using, for example, a P2P (Peer to Peer) method. The P2P method is a connection method in which multiple equivalent computers communicate directly one-to-one. A blockchain 81 is stored in each of the multiple computers included in the distributed network 8. Information is stored in the blockchain 81 using blockchain technology, and for example, a history of delivery during the distribution process in the production of personalized medicine is stored.

[0038] Since the terminals 1 to 5 have the same configuration, the configuration of the terminal 1 will be described below as a representative of the terminals 1 to 5. Fig. 2 is a schematic diagram of a terminal according to this embodiment. As shown in Fig. 2, the terminal 1 includes an input interface 11, a communication module 12, a storage device 13, a memory 14, an output interface 15, and a processor 16. While one embodiment of the terminal 1 will be described as including one processor 16, the terminal 1 may include multiple processors, i.e., one or more processors. While one embodiment of the terminal 1 will be described as including one storage device 13, the terminal 1 may include multiple processors, i.e., one or more storage devices.

[0039] The input interface 11 receives input from, for example, a person in charge at a genetic analysis institution, and outputs an input signal corresponding to the received input to the processor 16 . The communication module 12 is connected to the communication network CN and communicates with the management system 6 and the storage 9. This communication may be wired or wireless.

[0040] The storage device 13 is, for example, a storage device that stores programs, unique private keys, and various data to be read and executed by the processor 16. The memory 14 temporarily holds data and programs. The memory 14 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 15 can be connected to an external device and can output signals to the external device. The processor 16 loads programs from the storage device 13 into the memory 14 and executes a series of instructions included in the programs to perform various processes.

[0041] Fig. 3 is a schematic diagram of the management system of this embodiment. As shown in Fig. 3, the management system 6 includes an input interface 61, a communication module 62, a storage device 63, a memory 64, an output interface 65, and a processor 66. Note that, although one embodiment of the management system 6 is described here as including one processor 66, multiple processors may be included, i.e., one or more processors may be included. Also, one embodiment of the management system 6 is described here as including one storage device 63, but multiple processors may be included, i.e., one or more storage devices may be included.

[0042] The input interface 61 receives input from an administrator of the management system 6 (for example, an employee of the management organization), and outputs to the processor 66 an input signal corresponding to the received input. The communication module 62 is connected to the communication network CN and communicates with each of the terminals 1 to 5, the authentication system 7, the block chain 81, and the storage 9. This communication may be wired or wireless.

[0043] The storage device 63 is, for example, a storage device, and stores programs and various data to be read and executed by the processor 66. The memory 64 temporarily holds data and programs. The memory 64 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 65 can be connected to an external device and can output signals to the external device. The processor 66 loads programs from the storage device 63 into the memory 64 and executes a series of instructions included in the programs to perform various processes.

[0044] Fig. 4 is a schematic diagram of the authentication system of this embodiment. As shown in Fig. 4, the authentication system 7 includes an input interface 71, a communication module 72, a storage device 73, a memory 74, an output interface 75, and a processor 76. Note that, although one embodiment of the authentication system 7 will be described here as including one processor 76, multiple processors may be included, i.e., one or more processors may be included. Also, one embodiment of the authentication system 7 will be described here as including one storage device 73, but multiple processors may be included, i.e., one or more storage devices may be included.

[0045] The input interface 71 receives input from an administrator of the authentication system 7 (for example, an employee of the authentication organization), and outputs an input signal to the processor 76 in accordance with the received input. The communication module 72 is connected to the communication network CN and communicates with the management system 6 and the block chain 81. This communication may be wired or wireless.

[0046] The storage device 73 is, for example, a storage device, and stores programs to be read and executed by the processor 76, public keys corresponding to the private keys of the terminals 1 to 5 (i.e., five public keys), and various data. The memory 74 temporarily holds the data and programs. The memory 74 is a volatile memory, for example, a RAM (Random Access Memory). The output interface 75 can be connected to an external device and can output signals to the external device. The processor 76 loads programs from the storage device 73 into the memory 74 and executes a series of instructions included in the programs to perform various processes.

[0047] 5 is a schematic diagram showing an example of an outline of the process of creating a personalized medicine. In one embodiment, first, in response to a request from a terminal 4 used by a medical institution, a dragID, which is an example of drug identification information for identifying a personalized medicine, is issued from the management system 6.

[0048] First, the medical institution transfers the drug ID and the patient's specimen (also called the patient sample) to the logistics company. At that time, the following process is executed, for example. (Step S10) The terminal 4 transmits to the management system 6 information on the delivery of the specimen of the target patient. (Step S11) The management system 6 records the information received from the terminal 4 about the transfer of the specimen of this target patient in the block chain 81. (Step S12) The terminal 5 transmits to the management system 6 information about the receipt of the specimen of the target patient. (Step S13) The management system 6 records the information received from the terminal 5 about the receipt of the specimen of this target patient in the block chain 81.

[0049] Next, the logistics company delivers the drag ID and the patient's sample to the genetic analysis institution. At that time, the following process is performed, for example: (Step S20) The terminal 5 transmits to the management system 6 information on the delivery of the specimen of the target patient. (Step S21) The management system 6 records the information received from the terminal 5 about the transfer of the specimen of this target patient in the block chain 81. (Step S22) The terminal 1 transmits to the management system 6 information about the receipt of the specimen of the target patient. (Step S23) The management system 6 records the information received from the terminal 1 that the specimen of this target patient has been received in the block chain 81.

[0050] Next, a genetic analysis institution generates genome information of the target patient from the specimen of the genome target patient. In one embodiment, since the genome information has a large volume, identification information of the genome information is stored in the blockchain 81, and the genome information is stored in the storage 9. At this time, for example, the following process is executed. (Step S31) The management system 6 acquires the identification information of the genome information from the terminal 1 and records the identification information of this genome information in the blockchain 81. Here, the identification information of the genome information is, for example, a hash value of the genome information file encrypted by the terminal 1 with the private key of the terminal 1 (or the gene analysis institution) in step S160 of FIG. 6 described later. Note that the management system 6 may generate the identification information of this genome information. The genome information is stored in the storage 9 by, for example, the terminal 1 or the management system 6.

[0051] Next, the recipe creation institution creates a recipe for a personalized medicine (e.g., a vaccine, specifically, for example, a cancer vaccine). In one embodiment, the recipe for the personalized medicine is created by referencing the genome information from the genome information identification information. The personalized medicine recipe data is recorded in storage 9, and the genome information identification information is recorded in blockchain 81. At this time, for example, the following process is executed. (Step S33) The management system 6 acquires identification information for the genome information, for example, by referring to the blockchain 81. Here, the identification information for the genome information is, for example, a hash value of the genome information file encrypted by the terminal 1 with the private key of the terminal 1 (or the gene analysis institution) in step S160 of FIG. 6 described later. (Step S34) Then, the management system 6 transmits the identification information of the acquired genome information to the terminal 2. Thereafter, steps S210 to S260 in Fig. 6, which will be described later, are executed. (Step S41) Next, the management system 6 acquires recipe identification information of the personalized medicine (for example, a vaccine, specifically, for example, a cancer vaccine) from the terminal 2, and records this recipe identification information in the blockchain. Here, the recipe identification information is, for example, a hash value of a file of recipe data encrypted by the terminal 2 with the private key of the terminal 2 (or the recipe creation institution) in step S160 of FIG. 6, which will be described later. Note that the management system 6 may generate this recipe identification information. The recipe data of the personalized medicine is recorded in the storage 9 by the terminal 2 or the management system 6.

[0052] Next, the drug manufacturing institution manufactures the personalized drug (e.g., a vaccine, specifically, a cancer vaccine). The personalized drug recipe data is referenced from the personalized drug recipe identification information, and the drug manufacturing institution manufactures the personalized drug. At this time, for example, the following processing is executed. (Step S43) The management system 6 acquires recipe identification information, for example, by referring to the blockchain 81. Here, the recipe identification information is, for example, a hash value of a file of recipe data encrypted by the terminal 2 with the private key of the terminal 2 (or the recipe creation organization) in step S160 of FIG. 6 described later. (Step S44) Then, the management system 6 transmits the acquired recipe identification information to the terminal 3. Thereafter, steps S210 to S260 in Fig. 6, which will be described later, are executed. The terminal 3 refers to the recipe data of the personalized medicine from this recipe identification information and acquires it from the storage 9. The medicine manufacturing institution manufactures the personalized medicine from this personalized medicine recipe data.

[0053] When a drug manufacturing institution hands over the manufactured personalized medicine to a logistics company, for example, the following process is carried out. (Step S50) The terminal 3 transmits information about the delivery of the medicine to the management system 6. (Step S51) The management system 6 records the information on the transfer of the medicine received from the terminal 3 in the blockchain 81.

[0054] Next, when the logistics company receives the personalized medicine from the drug manufacturing institution, the following process is executed, for example. (Step S52) The terminal 5 transmits information that the medicine has been received to the management system 6. (Step S53) The management system 6 records the information about the receipt of the medicine received from the terminal 5 in the blockchain 81.

[0055] Next, when the logistics company delivers the personalized medicine to the medical institution, for example, the following process is executed. (Step S61) The terminal 5 transmits information about the delivery of the medicine to the management system 6. (Step S62) The management system 6 records the information on the transfer of the medicine received from the terminal 5 in the blockchain 81.

[0056] Next, when the medical institution receives the personalized medicine from the logistics company, for example, the following process is executed. (Step S63) The terminal 4 transmits information that the medicine has been received to the management system 6. (Step S64) The management system 6 records the information about the receipt of the medicine received from the terminal 4 in the blockchain 81.

[0057] In this way, information on the transfer of the target patient's sample or personalized medicine is recorded in the blockchain 81, and the transfer history is recorded without being erased or tampered with, so the correct history can be confirmed during or after the personalized medicine production process.

[0058] Furthermore, by recording the genome identification information or recipe identification information in the blockchain 81, the genome identification information or recipe identification information is recorded without being erased or tampered with. This makes it possible to obtain correct genome identification information or recipe identification information during or after the personalized medicine production process, so that the correct genome information or recipe data can be referenced and verified.

[0059] Figure 6 is a schematic diagram showing an example of the flow of transferring files of target content. This process is executed at each step of transferring the target content described above. As an example, the target content will be described as being genomic information of a target patient, the sender is terminal 1 used by a gene analysis institution, and the receiver is terminal 2 used by a recipe creation institution.

[0060] (Step S110) Terminal 1 transmits a sender ID, a receiver ID, and a drug ID, which is drug identification information, to management system 6. In this example, the sender ID is information that identifies the gene analysis institution that uses terminal 1, and the receiver ID is information that identifies the recipe creation institution that uses terminal 2.

[0061] (Step S120) Next, the management system 6 creates a directory for the target content (here, genome information as an example) in the storage 9.

[0062] (Step S130) Next, the management system 6 transmits the path of the created directory (also called a directory path) to the terminal 1.

[0063] (Step S140) Having received the directory path, the terminal 1 stores the file including the genome information in the directory indicated by the directory path in the storage 9.

[0064] (Step S150) Next, the terminal 1 transmits to the management system 6 the digital signature of the sender (here, as an example, the terminal 1 or the gene analysis institution) encrypted with the private key of the sender.

[0065] (Step S160) As an example, simultaneously or in parallel with this, terminal 1 transmits to management system 6 a hash value of the file encrypted with the private key of the sender (here, as an example, terminal 1 or the genetic analysis institution). Here, the hash value of the file is a hash value of the file of the target content (here, as an example, genome information). The hash value of the file encrypted with the private key of the sender (here, as an example, terminal 1 or the genetic analysis institution) is also referred to as an encrypted file hash value (S), with "(S)" added to the end to indicate that it was encrypted with the sender's private key.

[0066] (Step S170) <First Writing Step> Next, the management system 6 records the first proof data including the encrypted file hash value (S) in one block of the block chain 81. This process is a specific example of step S31 in FIG. 5.

[0067] An example of the first proof data written to the blockchain in the first writing step to the blockchain (step S180 in FIG. 6) is as follows: drugID: Drug identification information encryptedContentHashValue_S: The hash value of the target content (here, genome information as an example) encrypted with the sender's private key senderID: Sender ID (identification of the creator of the hash value) senderEsignature: The electronic signature of the sender (here, the genetic analysis institution as an example) receiverID: Identification information of the receiver (here, terminal 2 or recipe creation organization as an example) timestamp: The time of delivery location: location of delivery

[0068] Although the senderEsignature is the sender's electronic signature, it is not limited to this and may be the sender's electronic signature encrypted with the sender's private key.

[0069] (Step S180) Next, the management system 6 transmits the file path and the location of the record in the blockchain recorded in step S170 to the receiver terminal 2.

[0070] (Step S190) For example, the recipient terminal 2 requests the encrypted file hash value (S), and in response to this request, the management system 6 transmits the encrypted file hash value (S) and the block chain record to the terminal 2. Instead of the above processing of step S190, the management system 6 may transmit the encrypted file hash value (S) and the block chain record to the terminal 2 without a request from the terminal 2.

[0071] (Step S200) The terminal 2 also acquires from the storage 9 a file containing the target content (here, genome information as an example).

[0072] (Step S210) Next, terminal 2 decrypts the encrypted file hash value (S) using the public key and compares the decrypted value with the hash value of the file acquired in step S200 to determine whether they match. Here, the public key corresponds to the private key of the sender (here, terminal 1 or the genetic analysis institution, as an example) used in the encryption in step S150. If decryption is possible with the public key, it is proven that the encrypted file hash value (S) was created by the owner of the private key (here, terminal 1 or the genetic analysis institution, as an example). Furthermore, if the decrypted value matches the hash value of the file acquired in step S200, it is proven that the file acquired in step S200 is the true target content (here, genome information, as an example).

[0073] (Step S220) If the decrypted value in step S210 matches the hash value of the file acquired in step S200, the terminal 2 sends the recipient's digital signature encrypted with the recipient's private key (here, as an example, the recipe creation organization) to the management system 6.

[0074] (Step S230) As an example, simultaneously or in parallel with this, terminal 2 transmits to management system 6 a hash value of the file encrypted with the private key of the recipient (here, as an example, terminal 2 or the recipe creation institution). Here, the hash value of the file is a hash value of the file of the target content (here, as an example, genome information). The hash value of the file encrypted with the private key of the recipient (here, as an example, terminal 2 or the recipe creation institution) is also referred to as an encrypted file hash value (R), with "(R)" added to the end to indicate that it was encrypted with the recipient's private key.

[0075] (Step S240) <Second Writing Step> Next, the management system 6 records the second proof data including the encrypted file hash value (R) in one block of the block chain 81. The block recorded here is, for example, a block different from the block in step S170.

[0076] An example of the second proof data written to the blockchain in the second writing step of the blockchain (step S240 in FIG. 6) is as follows: drugID: Drug identification information encryptedContentHashValue_R: The hash value of the target content (here, genome information as an example) encrypted with the recipient's private key receiverEsignature: The digital signature of the receiver (here, the recipe creation organization as an example) timestamp: The time of the digital signature

[0077] Although the receiverEsignature is the receiver's digital signature, it is not limited to this and may be the receiver's digital signature encrypted with the receiver's private key.

[0078] (Step S250) The management system 6 transmits the target drag ID, the target content file (here, genome information as an example), the encrypted file hash value (S), and the encrypted file hash value (R) to the authentication system 7.

[0079] (Step S260) When authentication system 7 receives the target drag ID, the target content file (here, genome information as an example), the encrypted file hash value (S), and the encrypted file hash value (R), it verifies whether the transfer of the target content was performed properly for each transaction. If the verification results show that the transfer was performed properly, it certifies that the transfer of the target content was performed properly. Specifically, for example, authentication system 7 performs the following process. For example, authentication system 7 searches for a block in blockchain 81 using the drag ID, which is the target drug identification information, as a key. If the hash values ​​contained in the two blocks obtained as a result of the search match, it certifies that the transfer of the target content was performed successfully. Specifically, for example, authentication system 7 decrypts the encrypted file hash value (S) contained in one block with a public key corresponding to the private key of sender terminal 1 to obtain the file hash value (S), decrypts the encrypted file hash value (R) with a public key corresponding to the private key of receiver terminal 2 to obtain the file hash value (R), and determines whether the file hash value (S) and the file hash value (R) match.

[0080] This makes it possible to verify that the transfer of the target content (here, genomic information as an example) has been carried out appropriately, and if so, authenticate that this has been carried out appropriately. Note that, although the first proof data has been described as including the first hash value encrypted with the first private key as an example of information based on the first hash value, this is not limiting, and the first proof data may include the first hash value itself.

[0081] To summarize the above, the information processing system 10 is an information processing system including the terminal 1, the terminal 2, and the management system 6. The terminal 1 outputs a first hash value from data including at least the genomic information of the target patient, and transmits first certification data including the first hash value or information based on the first hash value (for example, the first hash value encrypted with a first private key). Here, the data including at least the genomic information of the target patient may include at least one of the type of disease, medical history, HLA type, and gender of the target patient. The management system 6 records the first certification data received from the terminal 1 in the blockchain. The management system 6 may transmit storage location data (for example, a file path) indicating the storage location of the genomic information to the terminal 2. The management system 6 reads the first certification data recorded in the blockchain and transmits the first certification data to the terminal 2. The terminal 2 obtains the first hash value from the first certification data received from the management system 6, reads the genomic information from, for example, a storage area indicated by the received storage location data, generates a second hash value from the genomic information, and determines whether the first hash value and the second hash value match.

[0082] With this configuration, if the first hash value recorded in the blockchain matches the second hash value generated from the genomic information, it is guaranteed that the two are the same genomic information, thereby ensuring the authenticity of the target patient's genomic information.

[0083] Furthermore, when transmitting the first certification data, terminal 1 transmits the first hash value encrypted with a first private key. When acquiring the first hash value included in the first certification data, terminal 2 acquires the first hash value by decrypting the first certification data with a first public key corresponding to the first private key. Note that the first public key may be held by terminal 2, or may be input to terminal 2 by a recipe creation institution that uses terminal 2.

[0084] With this configuration, the first private key is held only by the genetic analysis institution using terminal 1, thereby ensuring that the genetic analysis institution was involved in the encryption and that the genetic analysis institution was involved in the generation of the genome information as a party, i.e., ensuring the authenticity of the parties involved in the generation of the genome information.

[0085] Furthermore, the first certification data received from terminal 1 and recorded in the blockchain 81 includes drug identification information that identifies the personalized drug for the target patient. If the first hash value and the second hash value match, terminal 2 transmits second certification data including the drug identification information and the second hash value (specifically, for example, a file hash value or an encrypted file hash value (R)). In this case, since the second hash value and the first hash value match, it may be the first hash value that is transmitted instead of the second hash value. Next, the management system 6 records the second certification data received from terminal 2 in the blockchain.

[0086] With this configuration, in addition to the first proof data, the second proof data is also recorded in the blockchain. After that, by verifying whether the first hash value included in the first proof data recorded in the blockchain matches the second hash value included in the second proof data, it is possible to verify whether the transfer of genome information was carried out normally. This verification may be performed by the authentication system 7, for example.

[0087] Specifically, for example, as described above, the authentication system 7 may search for blocks in the blockchain using the target drug-identifying information as a key, and if the hash values ​​contained in the two blocks obtained as a result of the search match, it may determine that the transfer of the genome information has been carried out normally. With this configuration, it is possible to authenticate that the transfer of the genome information has been carried out normally.

[0088] 6, the target content is described as being genomic information of a target patient, the sender is terminal 1 used by a genetic analysis institution, and the receiver is terminal 2 used by a recipe creation institution, but this is not limited to this. The target content may be a vaccine recipe for a target patient, the sender may be terminal 2 used by a recipe creation institution, and the receiver may be terminal 3 used by a drug manufacturing institution. In this case, the series of processes in FIG. 6 may be as follows.

[0089] (Step S110) Terminal 2 transmits the sender ID, receiver ID, and drug ID, which is drug identification information, to management system 6. In this example, the sender ID is information that identifies the recipe creation institution that uses terminal 2, and the receiver ID is information that identifies the drug manufacturing institution that uses terminal 3.

[0090] (Step S120) Next, the management system 6 creates a directory in the storage 9 for the target content (here, recipe data as an example).

[0091] (Step S130) Next, the management system 6 transmits the path of the created directory (also called a directory path) to the terminal 3.

[0092] (Step S140) Having received the directory path, the terminal 3 stores a file including the recipe data in the directory of the storage 9 indicated by the directory path.

[0093] (Step S150) Next, the terminal 2 transmits to the management system 6 the digital signature of the sender (here, as an example, the terminal 2 or the recipe creation organization) encrypted with the private key of the sender.

[0094] (Step S160) As an example, simultaneously or in parallel with this, terminal 2 transmits to management system 6 a hash value of the file encrypted with the private key of the sender (here, as an example, terminal 2 or the recipe creation institution). Here, the hash value of the file is a hash value of the file of the target content (here, as an example, recipe data). The hash value of the file encrypted with the private key of the sender (here, as an example, terminal 2 or the recipe creation institution) is also referred to as an encrypted file hash value (S), with "(S)" added to the end to indicate that it was encrypted with the sender's private key.

[0095] (Step S170) <First Writing Step> Next, the management system 6 records the first proof data including the encrypted file hash value (S) in one block of the block chain 81. This process is a specific example of step S41 in FIG. 5.

[0096] An example of the first proof data written to the blockchain in the first writing step to the blockchain (step S180 in FIG. 6) is as follows: drugID: Drug identification information encryptedContentHashValue_S: The hash value of the target content (here, a file containing recipe data as an example) encrypted with the sender's private key senderID: Sender ID (identification of the creator of the hash value) senderEsignature: The digital signature of the sender (here, the recipe creation organization as an example) receiverID: Identification information of the receiver (here, terminal 3 or drug manufacturing institution as an example) timestamp: The time of delivery location: location of delivery

[0097] Although the senderEsignature is the sender's electronic signature, it is not limited to this and may be the sender's electronic signature encrypted with the sender's private key.

[0098] (Step S180) Next, the management system 6 transmits the file path and the location of the record in the blockchain recorded in step S170 to the receiver terminal 3.

[0099] (Step S190) For example, the recipient terminal 3 requests the encrypted file hash value (S), and in response to this request, the management system 6 transmits the encrypted file hash value (S) and the block chain record to the terminal 3. Instead of the above processing of step S190, the management system 6 may transmit the encrypted file hash value (S) and the block chain record to the terminal 3 without a request from the terminal 3.

[0100] (Step S200) The terminal 2 also acquires from the storage 9 a file including the target content (here, recipe data as an example).

[0101] (Step S210) Next, terminal 2 decrypts the encrypted file hash value (S) with the public key and compares the decrypted value with the hash value of the file acquired in step S200 to determine whether they match. Here, the public key corresponds to the private key of the sender (here, terminal 2 or the recipe creation institution, as an example) used in the encryption in step S150. If decryption is possible with the public key, it is proven that the encrypted file hash value (S) was created by the owner of the private key (here, terminal 2 or the recipe creation institution, as an example). Furthermore, if the decrypted value matches the hash value of the file acquired in step S200, it is proven that the file acquired in step S200 is the true target content (here, recipe data, as an example).

[0102] (Step S220) If the decrypted value in step S210 matches the hash value of the file obtained in step S200, the terminal 3 sends the recipient's electronic signature encrypted with the recipient's private key (here, a drug manufacturing organization as an example) to the management system 6.

[0103] (Step S230) As an example, simultaneously or in parallel with this, terminal 3 transmits a hash value of a file encrypted with the private key of the recipient (here, as an example, terminal 3 or a pharmaceutical manufacturing institution) to management system 6. Here, the hash value of the file is a hash value of the file of the target content (here, as an example, recipe data). Furthermore, the hash value of a file encrypted with the private key of the recipient (here, as an example, terminal 3 or a pharmaceutical manufacturing institution) is also referred to as an encrypted file hash value (R), with "(R)" added to the end to indicate that it was encrypted with the recipient's private key.

[0104] (Step S240) <Second Writing Step> Next, the management system 6 records the second proof data including the encrypted file hash value (R) in one block of the block chain 81. The block recorded here is, for example, a block different from the block in step S170.

[0105] An example of the second proof data written to the blockchain in the second writing step of the blockchain (step S240 in FIG. 6) is as follows: drugID: Drug identification information encryptedContentHashValue_R: The hash value of the target content (here, recipe data as an example) encrypted with the recipient's private key receiverEsignature: The electronic signature of the receiver (here, the drug manufacturing organization as an example) timestamp: The time of the digital signature

[0106] Although the receiverEsignature is the receiver's digital signature, it is not limited to this and may be the receiver's digital signature encrypted with the receiver's private key.

[0107] (Step S250) The management system 6 transmits to the authentication system 7 the target drag ID, the target content file (here, recipe data as an example), the encrypted file hash value (S), and the encrypted file hash value (R).

[0108] (Step S260) When the authentication system 7 receives the target drag ID, the target content file (here, recipe data as an example), the encrypted file hash value (S), and the encrypted file hash value (R), it verifies whether the transfer of the target content was performed properly for each transaction. If the verification results indicate proper transfer, it certifies that the transfer was performed properly. Specifically, for example, the authentication system 7 performs the following process. For example, the authentication system 7 searches the blockchain 81 for a block using the drag ID, which is the target drug identification information, as a key. If the hash values ​​contained in the two blocks obtained as a result of the search match, it certifies that the transfer of the target content was performed successfully. Specifically, for example, the authentication system 7 decrypts the encrypted file hash value (S) contained in one block with the public key corresponding to the private key of the sender terminal 2 to obtain the file hash value (S), decrypts the encrypted file hash value (R) with the public key corresponding to the private key of the receiver terminal 3 to obtain the file hash value (R), and determines whether the file hash value (S) and the file hash value (R) match.

[0109] This makes it possible to verify that the target content (here, recipe data as an example) has been transferred appropriately, and if so, authenticate that it has been transferred appropriately. Note that, although the third certification data has been described as including the third hash value encrypted with the third private key as an example of information based on the third hash value, the third certification data is not limited to this, and may include the third hash value itself.

[0110] In this way, the terminal 2 outputs a third hash value from data including at least a drug recipe (e.g., a vaccine recipe) for the target patient, and transmits third certification data including the third hash value or information based on the third hash value (e.g., the third hash value encrypted with a third private key). The management system 6 records the third certification data received from the terminal 2 in the blockchain. The management system 6 may also transmit storage location data (e.g., a file path) indicating the storage location of the recipe to the terminal 2. The management system 6 transmits the third certification data recorded in the blockchain to the terminal 3. The terminal 3 obtains the third hash value from the third certification data received from the management system 6, reads the recipe from the storage area indicated by the received storage location data, generates a fourth hash value from the recipe, and determines whether the third hash value and the fourth hash value match.

[0111] This configuration ensures that the first transaction recorded on the blockchain 3 Generated from a hash value and a recipe If the fourth hash value matches, it is guaranteed that the two are the same recipe. The authenticity of the product can be guaranteed.

[0112] Furthermore, when transmitting the third proof data, the terminal 2 uses the third hash value as a second private key In this case, the terminal 3 may transmit the encrypted data. When obtaining the third hash value, the third proof data is converted into a hash value corresponding to the second private key. The second public key is used to decrypt the 3 A hash value may be obtained.

[0113] With this configuration, the second private key is held only by the recipe creation institution using terminal 2, thereby ensuring that the recipe creation institution was involved in the encryption and that the recipe creation institution was involved in the creation of the recipe as a party, i.e., ensuring the authenticity of the parties involved in creating the recipe.

[0114] Furthermore, the third certification data received from terminal 2 and recorded in the blockchain 81 may include drug identification information that identifies the personalized medicine for the target patient. In this case, if the third hash value and the fourth hash value match, terminal 3 may transmit fourth certification data including the drug identification information and the third hash value or the fourth hash value. In this case, the management system 6 may record the fourth certification data received from terminal 3 in the blockchain.

[0115] With this configuration, in addition to the third proof data, the fourth proof data is also recorded in the blockchain. After that, by verifying whether the third hash value included in the third proof data recorded in the blockchain matches the fourth hash value included in the fourth proof data, it is possible to verify whether the recipe transfer transaction was carried out normally. This verification is performed, for example, by the authentication system 7.

[0116] Specifically, for example, the authentication system 7 may search for blocks in the blockchain using the target drug identification information as a key, and if the hash values ​​contained in the two blocks obtained as a result of the search match, it may determine that the transfer of the recipe has been successful. With this configuration, it is possible to authenticate that the transfer of the recipe has been successful.

[0117] Terminal 4 may also transmit fifth certification data to certify that the medical institution has handed over the target patient's sample to the logistics company. In this case, the management system 6 may record the fifth certification data received from terminal 4 in the blockchain 81. Furthermore, in this case, terminal 5 may transmit sixth certification data to certify that the logistics company has received the target patient's sample from the medical institution. Furthermore, in this case, the management system 6 may record the sixth certification data received from terminal 5 in the blockchain 81.

[0118] This configuration makes it possible to verify later that the transfer of the subject patient's sample was carried out normally.

[0119] Here, the fifth certification data may include a hash value of the personalized medicine text data encrypted with a third private key for the medical institution, and the sixth certification data may include a hash value of the personalized medicine text data encrypted with a fourth private key for the logistics company.

[0120] As described above, the information processing system 10 according to this embodiment is an information processing system including a first terminal, a second terminal, and a management system. The first terminal outputs a first hash value from data including at least the target content and transmits first proof data including either the first hash value or information based on the first hash value (e.g., the first hash value encrypted with a first private key). The management system records the first proof data received from the first terminal in a blockchain. The management system transmits the first proof data recorded in the blockchain to the second terminal. The second terminal acquires the first hash value from the first proof data received from the management system. If the information based on the first hash value included in the first proof data is the first hash value encrypted with a first private key, this acquisition process includes decrypting the first hash value with a first public key corresponding to the first private key. The second terminal then acquires the target content from, for example, a storage area of ​​a storage indicated by storage location data (e.g., a file path) received from the management system, generates a second hash value from the target content, and determines whether the first hash value and the second hash value match.

[0121] Here, the first terminal and the second terminal may be terminal 1 and terminal 2, or terminal 2 and terminal 3, or terminal 2 and terminal 3, or terminal 4 and terminal 5, or terminal 5 and terminal 1, or terminal 3 and terminal 4, or terminal 5 and terminal 4, respectively.

[0122] This means that if the first hash value recorded in the blockchain matches the second hash value generated from the target content, it is guaranteed that the two are the same target content, thereby ensuring the authenticity of the target content.

[0123] While the storage 9 has been described as being separate from the management system 6, this is not limiting and the storage 9 may be built into the management system 6. In the above-described embodiment, target content (e.g., genome information or recipe data) is exchanged via the storage 9 as an example. When the target content has a large amount of data, such as genome information, the exchange can be smoother by going through the storage 9. However, this is not limiting and the exchange may be performed without going through the storage 9. For example, the second terminal may directly receive the target content from the first terminal or the management system, or a user of the second terminal may physically receive a memory storing the target content by delivery or the like and store it in the second terminal. As long as the second terminal can acquire the target content, the acquisition route is not important.

[0124] At least a part of the management system 6 or the terminals 1 to 5 described in the above-described embodiment may be configured with hardware or software. When configured with software, a program that realizes at least a part of the functions of the management system 6 or the terminals 1 to 5 may be stored in a computer-readable recording medium and read and executed by a computer. The recording medium is not limited to removable media such as magnetic disks and optical disks, but may also be fixed recording media such as hard disk drives and memories.

[0125] In addition, a program that realizes at least some of the functions of the management system 6 or the terminals 1 to 5 may be distributed via a communication line (including wireless communication) such as the Internet. Furthermore, the program may be encrypted, modulated, or compressed and distributed via a wired line or wireless line such as the Internet, or stored on a recording medium.

[0126] Furthermore, the management system 6 may be operated by one or more information devices. When multiple information devices are used, one of the devices may be a computer, and the computer may execute a predetermined program to realize the functions of at least one means of the management system 6.

[0127] In the method invention, all processes (steps) may be realized by automatic control using a computer. Alternatively, each process may be performed by a computer, with progress control between processes being performed manually. Furthermore, at least some of the processes may be performed manually.

[0128] As described above, the present invention is not limited to the above-described embodiments, and the components can be modified and embodied in practice without departing from the spirit of the invention. Furthermore, various inventions can be formed by appropriately combining multiple components disclosed in the above-described embodiments. For example, some components may be omitted from all the components shown in the embodiments. Furthermore, components from different embodiments may be appropriately combined. [Explanation of symbols]

[0129] 1 device 10 Information Processing Systems 11 Input Interface 12 Communication Module 13 Storage device 14 Memory 15 Output Interface 16 processors 2. Devices 3. Terminal 4. Terminal 5. Terminal 6 Management System 61 Input Interface 62 Communication Module 63 Storage device 64 memory 65 Output Interface 66 processors 7 Authentication System 71 Input Interface 72 Communication Module 73 Storage device 74 memory 75 Output Interface 76 processors 8. Decentralized Networks 81 Blockchain 9. Storage

Claims

1. An information processing system comprising a first terminal used by a genetic analysis institution that generates genomic information of a target patient from a specimen of the target patient, a second terminal used by a recipe creation institution that creates a vaccine recipe, and a management system, the first terminal outputs a first hash value from data including at least target content that is genomic information of a target patient, and transmits first certification data including either the first hash value or information based on the first hash value; The management system records the first proof data received from the first terminal in a blockchain; The management system transmits the first proof data recorded in the blockchain to the second terminal; The second terminal acquires a first hash value from the first certification data received from the management system, acquires the target content, generates a second hash value from the target content, and determines whether the first hash value and the second hash value match. Information processing system.

2. The genomic information of the subject patient includes genetic data of cancer cells of the subject patient and genetic data of normal cells of the subject patient. The information processing system according to claim 1 .

3. the information based on the first hash value is obtained by encrypting the first hash value with a first private key, the first terminal transmits the first proof data by encrypting the first hash value with a first private key; When acquiring the first hash value included in the first proof data, the second terminal acquires the first hash value by decrypting the first proof data with a first public key corresponding to the first private key.

3. The information processing system according to claim 1 or 2.

4. The first certification data received from the first terminal and recorded in the blockchain includes drug identification information that identifies the personalized drug for the target patient, If the first hash value and the second hash value match, the second terminal transmits second certification data including medicine identification information and the first hash value or the second hash value; The management system records the second proof data received from the second terminal in a blockchain. The information processing system according to claim 1 .

5. Further comprising an authentication system; The authentication system searches the blockchain blocks using the target drug identification information as a key, and if the hash values ​​contained in the two blocks obtained as a result of the search match, it determines that the transfer of the target content has been successful. The information processing system according to claim 4 .

6. Further comprising a third terminal used by a drug manufacturing institution that manufactures personalized medicines from the vaccine recipe; the second terminal outputs a third hash value from data including at least a medicine recipe for the target patient, and transmits third certification data including either the third hash value or information based on the third hash value; The management system records the third proof data received from the second terminal in a blockchain; The management system transmits the third proof data recorded in the blockchain to the third terminal; The third terminal acquires a third hash value included in the third certification data received from the management system, acquires the recipe, generates a fourth hash value from the recipe, and determines whether the third hash value and the fourth hash value match.

3. The information processing system according to claim 1.

7. the second terminal encrypts the third hash value with a second private key when transmitting the third proof data; When acquiring the third hash value included in the third proof data, the third terminal acquires the third hash value by decrypting the third proof data with a second public key corresponding to the second private key. The information processing system according to claim 6.

8. The third certification data received from the second terminal and recorded in the blockchain includes drug identification information that identifies the personalized drug for the target patient, If the third hash value and the fourth hash value match, the third terminal transmits fourth certification data including medicine identification information and the third hash value or the fourth hash value; The management system records the fourth proof data received from the third terminal in a blockchain. The information processing system according to claim 6.

9. The system is equipped with a fourth terminal used by medical institutions and a fifth terminal used by logistics companies, the fourth terminal transmits fifth certification data for certifying that the specimen of the target patient has been handed over from the medical institution to the logistics company; The management system records the fifth proof data received from the fourth terminal in a blockchain; the fifth terminal transmits sixth certification data for certifying that the logistics company has received the specimen of the target patient from the medical institution; The management system records the sixth proof data received from the fifth terminal in a blockchain. The information processing system according to claim 1 .

10. the fifth certification data includes a hash value of text data for personalized medicine encrypted with a third private key for the medical institution, The sixth proof data includes a hash value of text data for personalized medicine encrypted with a fourth private key for the logistics company. The information processing system according to claim 9 .

11. A first terminal used by a genetic analysis institution that generates genomic information of a target patient from a sample from the target patient outputs a first hash value from data that includes at least target content, which is the genomic information of the target patient, and transmits first certification data that includes either the first hash value or information based on the first hash value; The management system records the first proof data received from the first terminal in a blockchain; The management system transmits the first certification data recorded in the blockchain to a second terminal used by a recipe creation organization that creates a vaccine recipe; the second terminal acquires a first hash value from the first certification data received from the management system, acquires the target content, generates a second hash value from the target content, and determines whether the first hash value and the second hash value match. An information processing method comprising:

12. A program for causing a computer to execute the information processing method according to claim 11.

13. An information processing system comprising a first terminal used by a recipe creation institution that creates a vaccine recipe, a second terminal used by a drug manufacturing institution that manufactures personalized medicines from the vaccine recipe, and a management system, the first terminal outputs a first hash value from data including at least target content that is a vaccine recipe for a target patient, and transmits first certification data including either the first hash value or information based on the first hash value; The management system records the first proof data received from the first terminal in a blockchain; The management system transmits the first proof data recorded in the blockchain to the second terminal; The second terminal acquires a first hash value from the first certification data received from the management system, acquires the target content, generates a second hash value from the target content, and determines whether the first hash value and the second hash value match. Information processing system.

Images